상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Antibody engineering for the development of therapeutic antibodies

Authors 

Sang Jick KimYoung Woo ParkHyo Jeong Hong

Publisher 

Springer Verlag (Germany)

Issue Date 

2005

Citation 

Molecules and Cells, vol. 20, no. 1, pp. 17-29

Keywords 

affinity Maturationantibody engineeringantibody fragmentseffector functionshuman monoclonal antibodieshumanized antibodiespharmacokineticstherapeutic antibodiesCD3 antibodychimeric antibody

Abstract 

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical product category after vaccines. Antibodies have been engineered by a variety of methods to suit a particular therapeutic use. This review describes the structural and functional characteristics of antibody and the antibody engineering for the generation and optimization of therapeutic antibodies.

ISSN 

1016-8478

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2017-04-19


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)